››Don't Let Market Access for your pharmaceutical assets be at risk.

Don't Let Market Access for your pharmaceutical assets be at risk

Each product in pharmaceuticual development will be an investment of upwards of $1.2 billion to overcome the first 3 hurdles of market access (efficacy, manufacturing and safety), yet every company leaves the 4th hurdle to chance or at best it is treated as a marketing after thought.

We have extensive experience in state-of-the-art market access strategic thinking - developing at pathway for market access early in human development, with a pathway which results in compelling data packages available soon after marketing authorization, the most critical time point for market access.  We have been involved in over 400 individual health technology assessments with over 90% success.

››We offer:

• Product strategic planning (Developmental and Marketed Products, Execution of studies, Development and compellation of market access data packages
• Specific development of country based health technology assessment packages (e.g. NICE, AMCP, PBAC, CDR).
• Consulting on the Organiztion of Market Access Groups and Processes.

Read about "value proposition", pharmacoepidemiology and the science of Outcomes Research through our services page

Local references available or just ask almost anyone in Outcomes Research about our reputation and experience - you will find someone pretty quickly.

Call us today for a FREE initial consultation!